Sciatica Market

Market Overview:

The 7 major sciatica markets reached a value of US$ 2.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 3.2 Billion by 2034, exhibiting a growth rate (CAGR) of 2.62% during 2024-2034.

The sciatica market has been comprehensively analyzed in IMARC's new report titled "Sciatica Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Sciatica refers to a type of nerve pain resulting from irritation or injury to the sciatic nerve, which runs down both legs from the lower back. It most commonly develops when a herniated disc or bone overgrowth puts pressure on a nerve region. The symptoms of this condition may vary from mild-moderate to severe. Some of the usual indications include shooting pain, weakness or numbness in the lower back, buttock, and down the leg, loss of movement, decreased bowel and bladder control, etc. Individuals suffering from sciatica may also experience gait dysfunction or pins and needles tingling sensation. Diagnosing this disease is typically done by identifying the patient’s clinical features and medical history, along with a physical exam, such as a straight-leg-raising test. Other diagnostic procedures, including spinal X-rays, magnetic resonance imaging (MRI), computed tomography (CT) scans, etc., are also used to visualize detailed pictures of bone and soft tissues of the back. The doctor may further perform nerve conduction velocity studies or myelograms to determine the cause of underlying indications.

The rising prevalence of nerve disorders, which leads to compression of a nerve root, is primarily driving the sciatica market. In addition to this, the increasing incidences of various risk factors, including aging, obesity, smoking, diabetes, sedentary lifestyles, etc., are also bolstering the market growth. Moreover, the widespread adoption of effective medications, such as non-steroidal anti-inflammatory drugs, opioid analgesics, muscle relaxants, systemic corticosteroids, etc., to ease pain among patients is acting as another significant growth-inducing factor. Apart from this, the inflating application of lumbar provocative discography, an invasive diagnostic tool that involves an injection of contrast media into the spine discs to aid in the specific detection of the ailment, is further propelling the market growth. Additionally, the escalating demand for non-pharmacological interventions, including chiropractic treatment techniques, acupuncture, stretching, etc., which can relax tense muscles and improve physical function, is creating a positive outlook for the market. Furthermore, the emerging popularity of non-opioid medication and implantable spinal pumps for treating the ailment, since they impart a potent effect on the affected area and help to relief underlying symptoms without the patient’s inconvenience, is expected to drive the sciatica market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the sciatica market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for sciatica and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the sciatica market in any manner.

Recent Developments:

• In September 2023, SpineThera, Inc. released groundbreaking findings from an independent market research study. The study highlights the immense potential of SpineThera's SX600, an innovative form of extended-release dexamethasone microspheres intended for transforaminal epidural injection in the treatment of sciatica.

Key Highlights:                                                                      

• The peak incidence of sciatica occurs in persons in their fourth decade.
• Lifetime incidence is estimated to be between 10% and 40%.
• The annual incidence ranges from 1% to 5%.
• This condition rarely occurs before the age of 20 unless a result of trauma.
• Physical exercise raises the incidence in those with prior sciatic complaints and lowers it in those with no prior symptoms.

Drugs:

SP-102 is a thick gel formulation containing dexamethasone sodium phosphate that is delivered by spinal injection. The experimental product is free of preservatives, surfactants, solvents, and particles.

SX600 (dexamethasone) is a unique formulation of extended-release microspheres intended for transforaminal epidural injection to treat sciatica pain.

Clonidine micropellets are an extended-release analgesic used to treat sciatica. The product is in phase 3 clinical trials.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the sciatica market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the sciatica market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current sciatica marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the sciatica market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the sciatica market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the sciatica market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of sciatica across the seven major markets?
• What is the number of prevalent cases (2018-2034) of sciatica by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of sciatica by gender across the seven major markets?
• What is the number of prevalent cases (2018-2034) of sciatica by type across the seven major markets?
• How many patients are diagnosed (2018-2034) with sciatica across the seven major markets?
• What is the size of the sciatica patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of sciatica?
• What will be the growth rate of patients across the seven major markets?
   

Sciatica: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for sciatica drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the sciatica market?
• What are the key regulatory events related to the sciatica market?
• What is the structure of clinical trial landscape by status related to the sciatica market?
• What is the structure of clinical trial landscape by phase related to the sciatica market?
• What is the structure of clinical trial landscape by route of administration related to the sciatica market?